Audet Juliette Berangere
SEC insider (Form 3/4/5 filer). CIK 0002000393. Chief Business Officer at NewAmsterdam Pharma Co N.V. (NAMS). 4 reported Form 4/5 transactions since Sep 2024; latest on May 1, 2025. Located in NAARDEN, P7.
Companies Audet Juliette Berangere has filed insider reports for
- NewAmsterdam Pharma Co N.V. (NAMS): Officer, Chief Business Officer
Audet Juliette Berangere
CIK: 0002000393
Transaction Breakdown
Open Market Buys (P)1 (25.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (75.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NAMS
NewAmsterdam Pharma Co N.V.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- May 1, 2025NAMS
NewAmsterdam Pharma Co N.V.
AwardDirectOption (right to buy)
30K shares- - Jan 7, 2025NAMS
NewAmsterdam Pharma Co N.V.
AwardDirect14K shares- - Jan 2, 2025NAMS
NewAmsterdam Pharma Co N.V.
AwardDirectOption (right to buy)
100K shares- - Sep 26, 2024NAMS
NewAmsterdam Pharma Co N.V.
PurchaseDirect1.1K shares at avg. $15.70$17K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 1, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award Option (right to buy) | 30,000 | - | - | Direct |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award | 14,000 | - | $0 | Direct |
| Jan 2, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award Option (right to buy) | 100,000 | - | - | Direct |
| Sep 26, 2024 | NAMS NewAmsterdam Pharma Co N.V. | Purchase | 1,104 | $15.70 | $17,333 | Direct |
1-4 of 4 transactions